Article Text

Download PDFPDF
Risk of severe liver injury with ▼ daclizumab (Zinbryta)

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a warning on the risk of severe liver injury with daclizumab.1 The MHRA has advised that, while an urgent EU-wide review of new information on liver safety is under way, initiation of daclizumab in multiple sclerosis (MS) should be restricted to patients with limited treatment options. Prescribers should promptly review patients already on treatment to assess whether it continues to be appropriate for them. The review should include a discussion with …

View Full Text